Lisa Rojkjaer, M.D., serves as Sangamo’s Chief Medical Officer, and oversees all clinical development and operations activities. She brings 23 years of industry experience across all stages of drug development with both biologics and small molecules in a variety of hematologic and immunologic indications, holding senior leadership positions in both clinical development and medical affairs in biotech and global pharmaceutical companies.

Prior to joining Sangamo, Dr. Rojkjaer served as Chief Medical Officer at Viracta Therapeutics and Nordic Nanovector, both publicly-traded precision oncology companies. Previously, she was the Global Clinical Program Head at Novartis Oncology, leading development and supporting the regulatory approval of Rydaptâ. Prior to joining Novartis, Dr. Rojkjaer served as Chief Medical Officer at Molecular Partners and was Vice President, Head of Clinical Development at MorphoSys AG. Earlier, at Novo Nordisk, she served as Director of Clinical Development, Hematology in the US and Head, Global Medical Affairs, Biopharmaceuticals while based in Denmark.

Dr. Rojkjaer holds a Doctor of Medicine degree from the University of Toronto, where she also completed her internal medicine and hematology fellowships.